SLSilverio Loreta

Silverio Loreta

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Silverio Loreta has a total of 4 co-authors. Here are the top co-authors by number of shared publications:

  • Alessandro Allegra

    Division of Hematology, Department of Human Pathology in Adulthood and Childhood “Gaetano Barresi”, University of Messina, 98125 Messina, Italy

    1 shared publication
  • Fabio Stagno

    Division of Hematology, Department of Human Pathology in Adulthood and Childhood “Gaetano Barresi”, University of Messina, Via Consolare Valeria 1, 98125 Messina, Italy

    1 shared publication
  • Gabriella Cancemi

    Hematology Unit, Department of Human Pathology in Adulthood and Childhood “Gaetano Barresi”, University of Messina, Via Consolare Valeria, 98125 Messina, Italy

    1 shared publication
  • Santino Caserta

    Hematology Unit, Department of Onco-Hematology, Azienda Ospedaliera of Cosenza, 87100 Cosenza, Italy

    1 shared publication

Latest Publications

  • Open Access

    Hematological Malignancies in Older Patients: Focus on the Potential Role of a Geriatric Assessment Management

    by Santino Caserta, Gabriella Cancemi, Silverio Loreta, Alessandro Allegra, Fabio Stagno

    Geriatric assessment management is a multidimensional tool used to evaluate prognosis for clinical outcomes and targets for interventions in older adults with cancer receiving chemotherapy. In this review, we evaluated the possible application of geriatric assessment management (GAM) in hematological malignancies. In older patients with Diffuse Large B Cell Lymphoma, GAM might be helpful in both predicting planned hospital admissions and improving quality of life. In chronic myeloid leukemia, the Charlson Comorbidity Index demonstrates how comorbidities could affect treatment compliance and overall outcomes. In multiple myeloma, the application of different scores such as the International Myeloma Working Group Frailty Index and the Revised Myeloma Comorbidity Index can identify frail patients who need suitable interventions in treatment plan (reducing drug dose or changing treatment). Therefore, including GAM in the management plan of older patients with hematological malignancies may direct and optimize cancer care.